Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Decarboxylase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Decarboxylase. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2010-019396-29 Sponsor Protocol Number: LAMP-PD Start Date*: 2010-05-18
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
    Full Title: Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk o...
    Medical condition: Patients with idiopathic Parkinson's Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002192-40 Sponsor Protocol Number: periodld001 Start Date*: 2006-07-13
    Sponsor Name:Zsolt Lohinai DMD PhD
    Full Title: New treatment of periodontitis by inhibition of lysine decarboxilase enzyme
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003547-38 Sponsor Protocol Number: ALLN-177-206 Start Date*: 2018-07-17
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia
    Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003643-23 Sponsor Protocol Number: CRO-06-76 - AB/GAD/21 Start Date*: 2006-06-14
    Sponsor Name:Abiogen Pharma S.p.A.
    Full Title: Efficacy and tolerability study of a novel CNS drug ABIO 08/01 administered for 8 weeks to patients with generalised anxiety disorders
    Medical condition: generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017571 GAD LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001673-15 Sponsor Protocol Number: 12473A Start Date*: 2008-09-18
    Sponsor Name:H. Lundbeck A/S
    Full Title: A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)
    Medical condition: Generalised Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017571 GAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003032-23 Sponsor Protocol Number: AADC-010 Start Date*: 2019-10-09
    Sponsor Name:National Taiwan University Hospital
    Full Title: A Phase I/II Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
    Medical condition: Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003072-39 Sponsor Protocol Number: NTUH-AADC-011 Start Date*: 2019-10-09
    Sponsor Name:National Taiwan University Hospital
    Full Title: A Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion
    Medical condition: Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000921-29 Sponsor Protocol Number: ALLN-177-302 Start Date*: 2019-11-12
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
    Medical condition: Enteric Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005509-79 Sponsor Protocol Number: VR040/2/003 Start Date*: 2006-12-21
    Sponsor Name:Vectura Group plc
    Full Title: A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patient...
    Medical condition: Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor “off” periods
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004582-33 Sponsor Protocol Number: VR040/2/002 Start Date*: 2006-11-03
    Sponsor Name:Vectura Group plc
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing ...
    Medical condition: Hypomobility (off or freezing) episodes associated with advanced Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000726-78 Sponsor Protocol Number: SPD488-401 Start Date*: 2004-12-02
    Sponsor Name:Shire Pharmaceuticals Group plc
    Full Title: A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair
    Medical condition: Facial Hirsutism in Women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021860-13 Sponsor Protocol Number: BIA-91067-301 Start Date*: 2010-11-11
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMIS...
    Medical condition: Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) AT (Completed) LV (Completed) DE (Completed) ES (Completed) PT (Completed) CZ (Completed) SK (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001034-14 Sponsor Protocol Number: 07/Q0803/31 Start Date*: 2007-08-10
    Sponsor Name:St George's Healthcare NHS Trust [...]
    1. St George's Healthcare NHS Trust
    2. SLA Pharma
    Full Title: The effect of omega-3 fatty acids on Barrett's oesophagus
    Medical condition: Barrett's oesophagus refers to changes in the lining of the lower oesophagus in response to injury caused by gastric reflux. It is a pre-malignant condition and has a well established link with ad...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004134 Barrett's esophagus LLT
    9.1 10004136 Barrett's oesophagitis with dysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000577-29 Sponsor Protocol Number: S187.3.001 Start Date*: 2007-04-27
    Sponsor Name:Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
    Full Title: A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with...
    Medical condition: Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005196-16 Sponsor Protocol Number: H8O-MC-GWBQ Start Date*: 2012-07-24
    Sponsor Name:Amylin Pharmaceuticals, Inc.
    Full Title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes
    Medical condition: Treatment of Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002748-10 Sponsor Protocol Number: AD-02-013 Start Date*: 2013-12-12
    Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati...
    Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004352-33 Sponsor Protocol Number: ALLN-177-301 Start Date*: 2018-07-18
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
    Medical condition: Enteric Hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002084-42 Sponsor Protocol Number: EFC13957 Start Date*: 2016-07-11
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: 6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and ...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) IT (Completed) DE (Completed) CZ (Completed) FR (Completed) ES (Completed) PL (Completed) SE (Completed) DK (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015162-57 Sponsor Protocol Number: P06153 Start Date*: 2011-03-02
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) SE (Prematurely Ended) BG (Completed) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:51:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA